DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20174600

Treatment outcome of tubercular lymphadenopathy cases treated under dots: a five year follow up study

Rajendra P. Takhar, Prateek Kothari, Shanti K. Luhadiya, Narendra K. Gupta

Abstract


Background: Treatment of tubercular lymphadenopathy consists of at least 6 months of therapy with antitubercular drugs as DOTS in India. Some studies recommend that extension of therapy for some time may lead to lesser recurrence and relapse. This study was planned to assess the outcome of DOTS therapy in lymph node tuberculosis (TB) cases treated under RNTCP and to find out the prevalence of relapse in these patients in southern Rajasthan.

Methods: This was a retrospective analysis of 275 cases of lymph node tuberculosis treated with DOTS under RNTCP. An immediate outcome of these cases was recorded and further traceable 81 patients were interviewed for long term outcome.

Results: In our study population, treatment completion rate was 93.09%, defaulter rate was 4% and death reported in 3.7% (3/81) cases. We observed relapse rate of 9.1% after treatment completion. A total of 7.04% patients received extended treatment and none of them had relapsed during our follow up.

Conclusions: Our study confirms that the efficacy of DOTS treatment is quite good in cases of tubercular lymphadenopathy but still requires review of programmatic strategy. An extension of antitubercular therapy is recommended because patients treated with DOTS had a little higher relapse rate in comparison to whom the treatment extended who had no recurrence and relapse.


Keywords


Antitubercular therapy, Directly observed therapy, Tubercular lymphadenopathy

Full Text:

PDF

References


Pulmonary and Critical Care Bulletin, Publishing by PGIMER, Chandigarh. 2005;9(4):2005.

BTS Research Committee: Short Course Chemotherapy for Tuberculosis of Lymph Nodes: A Conrolled Trial. Br Med J. 1985;290:1106-8.

Jawahar MS, Sivasubramanian S, Vijay V. Short course chemotherapy for tuberculous lymphadenitis in children. BMJ. 1990;301:359-62.

Dixit R, Sharma S, Jindal S. Efficacy of DOTS Cat (III) treatment regimen for tuberculous cervical lymphadenopathy in Indian RNTCP: 2007. ACCP.

Kabra SK, Lodha Rakesh, Seth V. Category based treatment of TB in children. Indian Prediatr. 2004; 41:927-37.

Verma SK, Prasad R, Kant Surya, Santosh K. A five year follow up study of RNTCP in Lucknow. Summaries of Papers. Indian J Tuberculosis. 2006; 53:163-74.

Jain NK, Bajpai A, Jain S. Outcomes of Category III and I in immunocompetent patients of tuberculous lymphadenopathy treated in Revised National Tuberculosis Control Programme. Lung India. 2010; 27:115-7.

Sharma S, Sarin R, Khalid UK, Singla N, Sharma PP. Clinical profile and treatment outcome of tuberculous lymphadenitis in children using DOTS strategy. Indian J Tuberc. 2010;57:4-11.

Verma SK, Kant S, Kumar S, Prasad R. A five-year follow-up study of Revised National Tuberculosis Control Programme of India at Lucknow. Indian J Chest Dis Allied Sci. 2008;50:195-7.

Kabra SK, Lodha R, Seth V. Category based treatment of tuberculosis in children. Indian Pediatr. 2005;42(3):299:299-300.

Kandala V, Kondapalli N, Kalagani Y, Kandala M. Directly observed treatment short course in immunocompetent patients of tuberculous cervical lymphadenopathy treated in revised national tuberculosis control programme. Lung India (2012) 29:109.

Dixit R. Efficacy of Category III treatment regimen for tuberculous cervical lymphadenopathy In Indian Revised National Tuberculosis Control Progamme (RNTCP); 2007:132.

Gupta PR. Difficulties in managing lymph node TB. Lung India. 2004;21:50-3.

Sharma SK. Text book of tuberculosis. 2nd ed; Jaypee Publishers; 2009:397-410.

Dhingra VK, Aggarrwal N, Chandra S. Trends of TB mortality in Delhi state after implementation of RNTCP. Souvenir SEAR NATCON. 2008;8-10:65.

Van Loenhout-Rooyackers JH, Laheij RJ, Richter C, Verbeek AL. Shortening the duration of treatment for cervical tuberculous lymphadenitis. Eur Respir J. 2000;15:192-5.